Wu Sharon Changshan, Münger Karl
Molecular Microbiology Program, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA 02111, USA.
Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA.
Cancers (Basel). 2021 Nov 14;13(22):5690. doi: 10.3390/cancers13225690.
Cancer/testis (CT) antigens exhibit selective expression predominantly in immunoprivileged tissues in non-pathological contexts but are aberrantly expressed in diverse cancers. Due to their expression pattern, they have historically been attractive targets for immunotherapies. A growing number of studies implicate CT antigens in almost all hallmarks of cancer, suggesting that they may act as cancer drivers. CT antigens are expressed in head and neck squamous cell carcinomas. However, their role in the pathogenesis of these cancers remains poorly studied. Given that CT antigens hold intriguing potential as therapeutic targets and as biomarkers for prognosis and that they can provide novel insights into oncogenic mechanisms, their further study in the context of head and squamous cell carcinoma is warranted.
癌胚/睾丸(CT)抗原在非病理情况下主要在免疫豁免组织中选择性表达,但在多种癌症中异常表达。由于其表达模式,它们历来是免疫疗法的有吸引力的靶点。越来越多的研究表明CT抗原几乎参与了癌症的所有特征,这表明它们可能是癌症驱动因子。CT抗原在头颈部鳞状细胞癌中表达。然而,它们在这些癌症发病机制中的作用仍研究不足。鉴于CT抗原作为治疗靶点和预后生物标志物具有引人入胜的潜力,并且它们可以为致癌机制提供新的见解,因此有必要在头颈部鳞状细胞癌的背景下对其进行进一步研究。